

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Broncus Holding Corporation

壑博医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2216)

VOLUNTARY ANNOUNCEMENT
BRONCUS COMPLETED THE FIRST-IN-MAN CLINICAL TRIAL
OF ITS TARGETED LUNG DENERVATION RADIOFREQUENCY
ABLATION SYSTEM

Broncus Holding Corporation (“**Broncus**” or the “**Company**”) is pleased to announce that it has completed the first-in-man clinical trial of its Targeted Lung Denervation (TLD) radiofrequency ablation system, which is expected to benefit patients with chronic obstructive pulmonary disease (“**COPD**”) worldwide. The clinical operation was completed by a team consisting of Professor Luo Fengming, Professor Liu Dan, Associate Professor Shen Yongchun and Dr. Zhu Hui of the Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University.

COPD is a common chronic respiratory disease. According to Frost & Sullivan, there was 219.2 million COPD patients worldwide in 2020.

Targeted Lung Denervation radiofrequency ablation for COPD treatment is an international leading emerging technology. It mainly realizes denervation through targeting deep tissue radiofrequency ablation in areas with rich bronchial vagus nerves, thus relieving airway obstruction in the lung and achieving the effect of COPD treatment.

Cautionary Statement: There is no assurance that Targeted Lung Denervation radiofrequency ablation system will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

ABOUT BRNCUS

Broncus, a pioneer in the interventional pulmonology medical device market, provides innovative lung solutions in China and globally. Founded in 2012, Broncus has assembled a management team with extensive experience in product development, clinical research and commercialization, and has developed into an enterprise with a China-US dual center. Through close ties with KOLs in the global respiratory interventional field and the establishment of a comprehensive relationship from innovative concepts to project development and implementation, the Company has built a respiratory interventional diagnosis and treatment product pipeline comprises of 17 products and major product candidates, and owned a diversified intellectual property portfolio of 476 patents and patent applications. In addition, Broncus, through clinical training and market education and with its strong brand promotion and commercialization capabilities, has sales to mainstream markets around the world such as the United States, Europe, and Australia.

Our vision is to become a global leader in the transformation of lung disease treatment. Our mission is to establish interventional diagnosis and treatment solutions as the gold standard for lung disease treatment.

By order of the Board of Directors
Broncus Holding Corporation
ZHAO Michael Yi Wei
Chairman

Hong Kong, September 30, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Mr. ZHAN Guowei and Mr. XU Hong as executive directors, Mr. ZHAO Michael Yi Wei as Chairman and non-executive director, Mr. ZI Zhenjun and Mr. ZHANG Ao as non-executive directors, and Dr. KAM Pok Man, Professor LAU Joseph Wan Yee and Dr. JI Jian as independent non-executive directors.